Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers

Ashley M. Hopkins, Andrew Rowland, Ganessan Kichenadasse, Michael D. Wiese, Howard Gurney, Ross A. McKinnon, Chris S. Karapetis, Michael J. Sorich

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Immune checkpoint inhibitors (ICI) are an important development in the treatment of advanced cancer. A substantial proportion of patients treated with ICI do not respond, and additionally patients discontinue treatment due to adverse effects. While many novel biological markers related to the specific mechanisms of ICI actions have been investigated, there has also been considerable research to identify routinely available blood and clinical markers that may predict response to ICI therapy. If validated, these markers have the advantage of being easily integrated into clinical use for nominal expense. Several markers have shown promise, including baseline and post-treatment changes in leucocyte counts, lactate dehydrogenase and C-reactive protein. While promising, the results between studies have been inconsistent due to small sample sizes, follow-up time and variability in the assessed markers. To date, research on routinely available blood and clinical markers has focussed primarily on ICI use in melanoma, the use of ipilimumab and on univariate associations, but preliminary evidence is emerging for other cancer types, other ICIs and for combining markers in multivariable clinical prediction models.

LanguageEnglish
Pages913-920
Number of pages8
JournalBritish Journal of Cancer
Volume117
Issue number7
DOIs
Publication statusPublished - 26 Sep 2017
Externally publishedYes

Fingerprint

Biomarkers
Therapeutics
Leukocyte Count
Research
C-Reactive Protein
Sample Size
Melanoma
Neoplasms

Bibliographical note

Copyright the Author(s) 2017. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

Keywords

  • biomarkers
  • clinicopathological
  • immune checkpoint inhibitors
  • melanoma
  • precision medicine

Cite this

Hopkins, Ashley M. ; Rowland, Andrew ; Kichenadasse, Ganessan ; Wiese, Michael D. ; Gurney, Howard ; McKinnon, Ross A. ; Karapetis, Chris S. ; Sorich, Michael J. / Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers. In: British Journal of Cancer. 2017 ; Vol. 117, No. 7. pp. 913-920.
@article{d0e2ca8d04704dcba5c65f78775c8a26,
title = "Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers",
abstract = "Immune checkpoint inhibitors (ICI) are an important development in the treatment of advanced cancer. A substantial proportion of patients treated with ICI do not respond, and additionally patients discontinue treatment due to adverse effects. While many novel biological markers related to the specific mechanisms of ICI actions have been investigated, there has also been considerable research to identify routinely available blood and clinical markers that may predict response to ICI therapy. If validated, these markers have the advantage of being easily integrated into clinical use for nominal expense. Several markers have shown promise, including baseline and post-treatment changes in leucocyte counts, lactate dehydrogenase and C-reactive protein. While promising, the results between studies have been inconsistent due to small sample sizes, follow-up time and variability in the assessed markers. To date, research on routinely available blood and clinical markers has focussed primarily on ICI use in melanoma, the use of ipilimumab and on univariate associations, but preliminary evidence is emerging for other cancer types, other ICIs and for combining markers in multivariable clinical prediction models.",
keywords = "biomarkers, clinicopathological, immune checkpoint inhibitors, melanoma, precision medicine",
author = "Hopkins, {Ashley M.} and Andrew Rowland and Ganessan Kichenadasse and Wiese, {Michael D.} and Howard Gurney and McKinnon, {Ross A.} and Karapetis, {Chris S.} and Sorich, {Michael J.}",
note = "Copyright the Author(s) 2017. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.",
year = "2017",
month = "9",
day = "26",
doi = "10.1038/bjc.2017.274",
language = "English",
volume = "117",
pages = "913--920",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Springer, Springer Nature",
number = "7",

}

Hopkins, AM, Rowland, A, Kichenadasse, G, Wiese, MD, Gurney, H, McKinnon, RA, Karapetis, CS & Sorich, MJ 2017, 'Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers', British Journal of Cancer, vol. 117, no. 7, pp. 913-920. https://doi.org/10.1038/bjc.2017.274

Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers. / Hopkins, Ashley M.; Rowland, Andrew; Kichenadasse, Ganessan; Wiese, Michael D.; Gurney, Howard; McKinnon, Ross A.; Karapetis, Chris S.; Sorich, Michael J.

In: British Journal of Cancer, Vol. 117, No. 7, 26.09.2017, p. 913-920.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Predicting response and toxicity to immune checkpoint inhibitors using routinely available blood and clinical markers

AU - Hopkins, Ashley M.

AU - Rowland, Andrew

AU - Kichenadasse, Ganessan

AU - Wiese, Michael D.

AU - Gurney, Howard

AU - McKinnon, Ross A.

AU - Karapetis, Chris S.

AU - Sorich, Michael J.

N1 - Copyright the Author(s) 2017. Version archived for private and non-commercial use with the permission of the author/s and according to publisher conditions. For further rights please contact the publisher.

PY - 2017/9/26

Y1 - 2017/9/26

N2 - Immune checkpoint inhibitors (ICI) are an important development in the treatment of advanced cancer. A substantial proportion of patients treated with ICI do not respond, and additionally patients discontinue treatment due to adverse effects. While many novel biological markers related to the specific mechanisms of ICI actions have been investigated, there has also been considerable research to identify routinely available blood and clinical markers that may predict response to ICI therapy. If validated, these markers have the advantage of being easily integrated into clinical use for nominal expense. Several markers have shown promise, including baseline and post-treatment changes in leucocyte counts, lactate dehydrogenase and C-reactive protein. While promising, the results between studies have been inconsistent due to small sample sizes, follow-up time and variability in the assessed markers. To date, research on routinely available blood and clinical markers has focussed primarily on ICI use in melanoma, the use of ipilimumab and on univariate associations, but preliminary evidence is emerging for other cancer types, other ICIs and for combining markers in multivariable clinical prediction models.

AB - Immune checkpoint inhibitors (ICI) are an important development in the treatment of advanced cancer. A substantial proportion of patients treated with ICI do not respond, and additionally patients discontinue treatment due to adverse effects. While many novel biological markers related to the specific mechanisms of ICI actions have been investigated, there has also been considerable research to identify routinely available blood and clinical markers that may predict response to ICI therapy. If validated, these markers have the advantage of being easily integrated into clinical use for nominal expense. Several markers have shown promise, including baseline and post-treatment changes in leucocyte counts, lactate dehydrogenase and C-reactive protein. While promising, the results between studies have been inconsistent due to small sample sizes, follow-up time and variability in the assessed markers. To date, research on routinely available blood and clinical markers has focussed primarily on ICI use in melanoma, the use of ipilimumab and on univariate associations, but preliminary evidence is emerging for other cancer types, other ICIs and for combining markers in multivariable clinical prediction models.

KW - biomarkers

KW - clinicopathological

KW - immune checkpoint inhibitors

KW - melanoma

KW - precision medicine

UR - http://www.scopus.com/inward/record.url?scp=85029902764&partnerID=8YFLogxK

U2 - 10.1038/bjc.2017.274

DO - 10.1038/bjc.2017.274

M3 - Article

VL - 117

SP - 913

EP - 920

JO - British Journal of Cancer

T2 - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 7

ER -